Table 3.

Rates of metastatic progression among men with clinical stage I/II disease

Group	Number at Risk	Number with Progression	Rate per 10,000 PY (95% CI)	Rate Ratio (95% CI)	10 Year probability of metastatic progression (95% CI), %
All	6060	203	46.8 (40–53)	N/A	4.9 (4.1–5.6)
Control Arm	2825	98	50.5 (41–61)	Ref	5.0 (3.9–6.1)
Intervention Arm	3235	105	43.7 (35–52)	0.87 (0.65– 1.14)	4.7 (3.7–5.7)
Gleason Category 1
Gleason 2–6	3816	60	20.6 (15–26)	Ref	2.1 (1.5–2.7)
Gleason 7	1605	79	78.6 (61–96)	3.8 (2.7–5.4)	8.3 (6.3–10.3)
Gleason 8–10	549	61	182.7 (137–229)	8.8 (6.2–12.7)	17.2 (12.7–21.7)
PSA at Diagnosis 2
<6 ng/ml	2803	55	27.7 (20–35)	Ref	3.0 (2.1–3.9)
6–10 ng/ml	1876	71	52.9 (41–65)	1.9 (1.3– 2.7)	5.3 (4.0–6.7)
>10 ng/ml	1062	61	79.2 (59–99)	2.9 (2.0– 4.2)	8.4 (6.1–10.7)

^1.Based on biopsy Gleason score. 90 men had unknown Gleason score, of whom 3 had progression.

^2.319 men had unknown diagnostic PSA, of whom 16 had progression.